Clinical trials: Oxycodone
Back Pain
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and immediate release oxycodone/acetaminophen…
- Trial name
- NCT00315874
- Testing
- Buprenorphine transdermal delivery system
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- Purdue Pharma LP
Cancer, Pain
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient's specific type of "chronic cancer pain".
- Conditions
- Cancer, Pain, Constipation
- Trial name
- NCT00513656
- Testing
- Oxycodone, Oxycodone/Naloxone
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Pain, Nausea
Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain
This is a double-blind, randomized, multiple-dose, placebo- and positive-controlled study of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) in patients with moderate to severe pain following surgical removal of…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT01780428
- Testing
- CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Charleston Laboratories, Inc
Moderate to Severe Pain Due to Diabetic Polyneuropathy
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.
- Trial name
- NCT00944697
- Testing
- Oxycodone Naloxone
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Postoperative Pain
OxyNorm Capsules in Post-Operative Pain Study
The efficacy and safety of oxycodone capsules compared with morphine tablets in hospitalized patients with moderate to severe pain following surgery.
- Trial name
- NCT01675635
- Testing
- OxyNorm Capsules, Morphine tablet
- Volunteers
- 240 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Healthy, Opioid Use
Buprenorphine-Fentanyl Interaction Study
An increase in overdose deaths has been attributed to widespread access to fentanyl and carfentanyl. The study is designed to determine if buprenorphine can change the respiratory depression response to intravenous (IV) fentanyl.
- Trial name
- NCT03747341
- Testing
- Buprenorphine Injectable Solution - Part A, Fentanyl - Part A, Ondansetron - Parts A + B
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Postoperative Pain
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
This is a randomized, double-blind, multicenter, repeat-dose study of fixed doses of Q8003 12 mg/8 mg given q6hr compared to morphine sulfate 24 mg and oxycodone hydrochloride 16 mg given q6hr for the management of acute moderate…
- Trial name
- NCT01280331
- Testing
- Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
- Where
- 4 sites in United States
- Volunteers
- 375 people
- Sponsor
- QRxPharma Inc.
Low Back Pain
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate…
- Trial name
- NCT00449176
- Testing
- tapentadol (CG5503) ER, oxycodone CR
- Volunteers
- 981 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pain
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
The objective of this study is to characterize the pharmacokinetics and to evaluate the safety of single and multiple doses of Oxycodone Oral Solution in pediatric and adolescent subjects for postoperative pain.
- Trial name
- NCT01959204
- Testing
- Oxycodone
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- VistaPharm, Inc.
Spinal Disorders
An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
Study Objectives: 1. Primary objective To assess the pain reduction after 8 weeks treatment from baseline (week 0) 2. Secondary objectives To assess the pain reduction after 4 weeks treatment from baseline (week 0) To assess the…
- Trial name
- TALENT (NCT01811238)
- Testing
- Oxycodone/naloxone
- Volunteers
- 240 people
- Sponsor
- Mundipharma Korea Ltd
Pain
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of four PF-00345439 formulations and oxycodone in solution
- Trial name
- NCT01552850
- Testing
- Oxycodone
- Where
- Singapore
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in…
- Trial name
- NCT00312221
- Testing
- Buprenorphine, oxycodone immediate-release
- Where
- 23 sites in United States
- Volunteers
- 418 people
- Sponsor
- Purdue Pharma LP
Healthy
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
- Trial name
- NCT01677065
- Testing
- Oxycodone controlled-release test formulation, Immediate-release reference drug
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Back Pain Lower Back Chronic
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in…
- Trial name
- NCT00313014
- Testing
- Buprenorphine, Oxycodone Immediate-Release
- Where
- 85 sites in United States
- Volunteers
- 660 people
- Sponsor
- Purdue Pharma LP
Healthy
A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users
The main purpose of this study is to simulate if oxycodone and naltrexone combination capsules (ALO-02) were to be tampered with by dissolving and then injecting intravenously for the purpose of getting high.
- Trial name
- NCT01825447
- Testing
- Oxycodone + Naltrexone, Oxycodone
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Pfizer
Back Pain Lower Back Chronic
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01125917
- Testing
- Buprenorphine transdermal patch
- Where
- 84 sites in United States
- Volunteers
- 354 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis, Knee, Osteoarthritis, Hip
An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)
The purpose of this study was to characterize the effectiveness and safety of OROS hydromorphone HCL and OxyContin in patients with chronic osteoarthritis (OA) of the knee or hip who are receiving chronic nonsteroidal…
- Trial name
- NCT00399048
- Testing
- OROS hydromorphone HCL ; OxyContin
- Volunteers
- 140 people
- Sponsor
- Alza Corporation, DE, USA
Opioid Related Disorders, Opiate Addiction
Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers
A study will be performed to evaluate changes in prescribing behavior of prescribers of ER/LA opioids
- Conditions
- Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02920762
- Testing
- on-interventional study - retrospective database review
- Volunteers
- 5,575,834 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Healthy
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) relative to the original OxyContin® (OXY) formulation (80 mg) in the fasted state.
- Trial name
- NCT01101191
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP